Authors : Heri Munajib; Wardah Rahmatul Islamiyah; J Eko Wahono

Volume/Issue : Volume 6 - 2021, Issue 11 - November

Google Scholar : http://bitly.ws/gu88

Scribd : https://bit.ly/3y7DdYN

Abstract : Valproic acid is commonly used in epilepsy patients, both focal and generalized epilepsy, in many cases, female epilepsy patients receiving valproic acid therapy are not easy to replace valproic acid therapy with other AEDs, therefore, when epilepsy patients are faced with a program pregnancy often treatment with valproic acid is unavoidable. The FDA's statement for pregnant women with valproic acid is category X. Based on this fact, how data and profiles of epilepsy patients in Indonesia are still rarely found. supplementation of high doses of folic acid and other minerals is very helpful in minimizing the teratogenic effects of valproic acid for infants for patients with epilepsy. Objective: To report clinical and epidemiological the use of valproic acid in pregnant women in the outpatient clinic at DR. Soetomo Hospital between 2017-2020. Methods: This is a retrospective study. All patients who were treated in outpatient care unit in January 2017- September 2020 Results: We obtained data from 2017-2020, 25 pregnant women with a history of epilepsy, data obtained 25 of them received valproic acid, 20 babies gave birth with live babies and 5 babies died, IUGR 8 babies, congenital malformations were found in 6 babies with 4 babies having congenital malformations from pregnant women with a history of epilepsy receiving valproic acid therapy. Conclusion: Management Before Conception and supplementation of Folic acid 1 mg/day for epileptic patient during pregnancy can reduce the risk malformation congenital in the baby

Keywords : Epileptic patient with pregnancy, DR Soetomo Hospital, Valproic acid, Folic acid.